Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA.
Expert Rev Mol Diagn. 2011 Jan;11(1):65-78. doi: 10.1586/erm.10.104.
Traumatic brain injury is a major health and socioeconomic problem that affects all societies. However, traditional approaches to the classification of clinical severity are the subject of debate and are being supplemented with structural and functional neuroimaging, as the need for biomarkers that reflect elements of the pathogenetic process is widely recognized. Basic science research and developments in the field of proteomics have greatly advanced our knowledge of the mechanisms involved in damage and have led to the discovery and rapid detection of new biomarkers that were not available previously. However, translating this research for patients' benefits remains a challenge. In this article, we summarize new developments, current knowledge and controversies, focusing on the potential role of these biomarkers as diagnostic, prognostic and monitoring tools of brain-injured patients.
颅脑损伤是一个影响所有社会的主要健康和社会经济问题。然而,临床严重程度的传统分类方法是有争议的,并且正在用结构和功能神经影像学来补充,因为广泛认识到需要反映发病过程要素的生物标志物。基础科学研究和蛋白质组学领域的发展极大地提高了我们对损伤相关机制的认识,并导致了以前无法获得的新生物标志物的发现和快速检测。然而,将这项研究转化为患者的获益仍然是一个挑战。在本文中,我们总结了新的进展、当前的知识和争议,重点介绍了这些生物标志物作为脑损伤患者的诊断、预后和监测工具的潜在作用。